These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12842959)

  • 1. Strategy for randomised clinical trials in rare cancers.
    Tan SB; Dear KB; Bruzzi P; Machin D
    BMJ; 2003 Jul; 327(7405):47-9. PubMed ID: 12842959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do we need randomised trials for rare cancers?
    Prasad V; Oseran A
    Eur J Cancer; 2015 Jul; 51(11):1355-7. PubMed ID: 25963018
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trials and rare diseases.
    Lagakos SW
    N Engl J Med; 2003 Jun; 348(24):2455-6. PubMed ID: 12802033
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation.
    Booth CM; Ohorodnyk P; Zhu L; Tu D; Meyer RM
    Eur J Cancer; 2011 Apr; 47(6):854-63. PubMed ID: 21296570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
    Bogaerts J; Sydes MR; Keat N; McConnell A; Benson A; Ho A; Roth A; Fortpied C; Eng C; Peckitt C; Coens C; Pettaway C; Arnold D; Hall E; Marshall E; Sclafani F; Hatcher H; Earl H; Ray-Coquard I; Paul J; Blay JY; Whelan J; Panageas K; Wheatley K; Harrington K; Licitra L; Billingham L; Hensley M; McCabe M; Patel PM; Carvajal R; Wilson R; Glynne-Jones R; McWilliams R; Leyvraz S; Rao S; Nicholson S; Filiaci V; Negrouk A; Lacombe D; Dupont E; Pauporté I; Welch JJ; Law K; Trimble T; Seymour M
    Eur J Cancer; 2015 Feb; 51(3):271-81. PubMed ID: 25542058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Purposefulness of using fuzzy logic approaches in the rare disease clinical trials].
    Kiseleva TS; Pagava KI; Korinteli IA; Korinteli MG; Shonvadze DN
    Georgian Med News; 2011 Apr; (193):22-4. PubMed ID: 21617269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International rare cancers initiative.
    Keat N; Law K; Seymour M; Welch J; Trimble T; Lascombe D; Negrouk A
    Lancet Oncol; 2013 Feb; 14(2):109-10. PubMed ID: 23369681
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomised controlled trials (RCTs)--essentials.
    Chan YH
    Singapore Med J; 2003 Feb; 44(2):60-3. PubMed ID: 14503778
    [No Abstract]   [Full Text] [Related]  

  • 9. Can external and subjective information ever be used to reduce the size of randomised controlled trials?
    Tan SB; Wee J; Wong HB; Machin D
    Contemp Clin Trials; 2008 Mar; 29(2):211-9. PubMed ID: 17720629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dangers of subgroup analysis.
    Stephens R
    Lancet Oncol; 2001 Jan; 2(1):9. PubMed ID: 11905629
    [No Abstract]   [Full Text] [Related]  

  • 11. Concealed allocation in randomised trials.
    Elkins M
    J Physiother; 2013 Jun; 59(2):134-6. PubMed ID: 23663807
    [No Abstract]   [Full Text] [Related]  

  • 12. Issues in the planning and conduct of randomised trials.
    Bhandari M; Pape HC; Giannoudis PV
    Injury; 2006 Apr; 37(4):349-54. PubMed ID: 16487524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential monitoring of randomization tests: stratified randomization.
    Zhang Y; Rosenberger WF; Smythe RT
    Biometrics; 2007 Sep; 63(3):865-72. PubMed ID: 17825016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The simplest statistical test: how to check for a difference between treatments.
    Pocock SJ
    BMJ; 2006 May; 332(7552):1256-8. PubMed ID: 16735336
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamic comparison of Kaplan-Meier proportions: monitoring a randomized clinical trial with a long-term binary endpoint.
    Brittain E; Follmann D; Yang S
    Biometrics; 2008 Mar; 64(1):189-97. PubMed ID: 17680830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should clinical trials be approached differently for rare cancers?
    Olver I
    Future Oncol; 2016 May; 12(10):1207-9. PubMed ID: 26939845
    [No Abstract]   [Full Text] [Related]  

  • 17. Collaboration is key to treating uncommon cancers: scientists and patients champion research in these rare diseases.
    Printz C
    Cancer; 2010 Jun; 116(12):2847-9. PubMed ID: 20564387
    [No Abstract]   [Full Text] [Related]  

  • 18. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical analysis of Goal Attainment Scaling endpoints in randomised trials.
    Urach S; Gaasterland C; Posch M; Jilma B; Roes K; Rosenkranz G; Van der Lee JH; Ristl R
    Stat Methods Med Res; 2019 Jun; 28(6):1893-1910. PubMed ID: 29921167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Randomised phase II trials in oncology].
    Piedbois P
    Bull Cancer; 2007 Nov; 94(11):953-6. PubMed ID: 18055312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.